XL335

Confirm delete?

XL335

Zoom

Cat No: 23350

Biochemicals - Receptor Pharmacology

XL335 is an orally bioavailable and potent agonist of the farnesoid X receptor (FXR) with an EC50 value of 4 nM in CV-1 cells transfected with human FXR.{37177} It is selective for FXR over a panel of 15 nuclear receptors at concentrations up to 10 μM...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

3-(3,4-difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethyl-azepino[4,5-b]indole-5-carboxylic acid, 1-methylethyl ester

Correlated keywords:

XL-335 WAY362450 FXR-450 CV1 m-RNA

Product Overview:
XL335 is an orally bioavailable and potent agonist of the farnesoid X receptor (FXR) with an EC50 value of 4 nM in CV-1 cells transfected with human FXR.{37177} It is selective for FXR over a panel of 15 nuclear receptors at concentrations up to 10 μM. XL335 induces expression of mouse intestinal bile acid binding protein (IBABP), human bile salt excretory pump (BSEP), and small heterodimer partner (SHP) genes in reporter gene assays. It also induces a 20-, 13-, and 2-fold increase in mRNA expression for IBABP, BSEP, and SHP, respectively, at a concentration of 1 μM. XL335 (3 mg/kg) reduces plasma cholesterol and triglycerides by 39 and 50%, respectively, and decreases the area of pre-atherosclerotic lesions in LDLR-/- mice fed a Western diet. It also decreases hepatic fibrosis in a mouse model of non-alcoholic steatohepatitis.{37178}

Size	5 mg
Shipping	dry ice
CAS Number	629664-81-9
Molecular Formula	C₂₅H₂₄F₂N₂O₃
SMILES	O=C(OC(C)C)C1=CN(C(C2=CC(F)=C(F)C=C2)=O)CC(C)(C)C3=C1NC4=C3C=CC=C4
Molecular Weight	438,5
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.